A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-over Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on the QTc Intervals in Healthy Subjects

Trial Profile

A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-over Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on the QTc Intervals in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Oliceridine (Primary) ; Moxifloxacin
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Sponsors Trevena
  • Most Recent Events

    • 17 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top